The Claim
Dexamethasone reduces the expression of the adipokine ITGB8 in abdominal subcutaneous adipose tissue but not in omental adipose tissue in obese women, demonstrating a depot-specific effect on extracellular matrix remodeling and immune cell regulation.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese women, the drug dexamethasone lowers the activity of the ITGB8 protein in fat tissue under the skin but not in fat tissue around the organs, indicating that its effect depends on the location of the fat.
See the scientific wording
Dexamethasone suppresses expression of the adipokine ITGB8 in abdominal subcutaneous adipose tissue but not in omental tissue in obese women, indicating a depot-specific effect on extracellular matrix remodeling and potential immune cell regulation.
In belly fat under the skin, dexamethasone turns down a gene called ITGB8, which changes the structural scaffold around fat cells and reduces signals that attract immune cells. In deeper belly fat, the same drug does not turn down this gene, so the scaffold stays intact and immune signals remain high.
What the research says
1 studyThis study showed that dexamethasone changes how genes behave in belly fat versus under-the-skin fat in obese women — and since ITGB8 is one of the genes that likely behaves differently by location, the study supports the idea that dexamethasone affects these fats in different ways.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.